Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. - Test2 - elhamkhani - TriplyDB

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

http://www.wikidata.org/entity/Q42457867

about

KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1 BRCA1 is a negative modulator of the PRC2 complex From RNA-seq reads to differential expression results Mammary gland development Mammary Development and Breast Cancer: A Wnt Perspective Stem cell technology in breast cancer: current status and potential applications Retinoblastoma tumor suppressor functions shared by stem cell and cancer cell strategies Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer P-cadherin and the journey to cancer metastasis Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management Triple negative breast cancer: looking for the missing link between biology and treatments Of mice and women: a comparative tissue biology perspective of breast stem cells and differentiation Steroid hormones, steroid receptors, and breast cancer stem cells Form and function: how estrogen and progesterone regulate the mammary epithelial hierarchy The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes ERrrr…where are the progenitors? Hormone receptors and mammary cell heterogeneity BRCA1 and estrogen/estrogen receptor in breast cancer: where they interact?The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance Adult lung stem cells and their contribution to lung tumourigenesis Mammary gland stem cells: more puzzles than explanations Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer SLUG: Critical regulator of epithelial cell identity in breast development and cancer Prostate cancer and parasitism of the bone hematopoietic stem cell niche Mammary stem cells and the differentiation hierarchy: current status and perspectives Links between cancer stem cells and epithelial-mesenchymal transition Normal morphogenesis of epithelial tissues and progression of epithelial tumors.Ductal barriers in mammary epithelium Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research Patient-derived xenograft models of breast cancer and their predictive power Scribble modulates the MAPK/Fra1 pathway to disrupt luminal and ductal integrity and suppress tumour formation in the mammary gland Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells.The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation Reversible interconversion and maintenance of mammary epithelial cell characteristics by the ligand-regulated EGFR system.A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.Mammary gland stem cells and their application in breast cancer CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis A phenotypic mouse model of basaloid breast tumors

P2860

Q24296484-1C1B5EB0-6851-4DCB-A159-09AB17B091BE Q24338768-5EA9875B-9053-4035-90E8-FE676A1552F2 Q24339430-5CED4735-9B5D-411A-B5F4-EA5C101C5604 Q24612983-2847BBCA-728B-4A2A-B399-8F1C2D9D1F36 Q24629797-2160421F-B4E9-4A5E-915C-B4146405D5F4 Q26740086-E6AE0969-2E80-42D5-8E56-939E60B6EAA9 Q26746223-065DF46F-1978-4973-BC1E-479A6C0B032A Q26750380-5E3B0CC2-9D37-4338-B807-A7C10C46F86C Q26766266-0F1BB3B3-EFC8-44F9-809B-0B6D64F9908B Q26781906-8CD5FFFD-0DD5-4AFF-B42B-8AF004D242F3 Q26782664-CD2CFF6F-A957-44F4-8117-18ADA2A709AB Q26783122-1BB8708E-1194-4A11-8A5B-D6B138AD59D7 Q26796835-AC8C05D8-533E-4526-9E06-72F6A8AD0E73 Q26799113-677B2708-CE81-4F6D-859E-38B4D572C8A2 Q26799290-36AD54FC-7445-4B56-90B0-D131DC7DA68C Q26799993-9A74DBD2-1E40-4F88-BF7C-75489CE117DB Q26801713-CF3F10BC-9B8A-42E3-B3F2-CC7B7E047915 Q26822737-317ADF92-2B7A-42A1-90CF-8B63632CBCCB Q26824147-0525EF3F-CF32-4258-950B-1CC6D24808A1 Q26824386-D2DB0A0B-5DD1-4FBD-BB60-ABFC1E4F4681 Q26830034-3CB37224-2302-48EE-B9BA-6888FD7AE9D3 Q26830779-1A34C0E6-4909-431B-92AE-52D7CC50A2A5 Q26860821-A9D5C19D-BA1C-4D2D-AAB3-BC5D22E8EBC8 Q26865846-F647C015-C6CE-4398-9963-B9455620363B Q26996231-76ACDACD-8684-4703-87AB-0E0E3AB33AFC Q27003345-CDF13E81-6DB8-4BFA-ADFB-7E9DAE1D2809 Q27004529-C4D6E942-CD11-4FE4-90C0-D4C415024D2E Q27015094-BA931C92-6F99-4DD7-AAEB-EDA5F3C96A78 Q27023960-04DAA1EB-31D4-45CE-BB25-F2AB22B24AE7 Q27024191-20A5BC16-5560-4DBD-91AA-8D8B3CC81B58 Q27026531-9FBAFD7D-DCD1-44F3-B9AC-0EE828D4A234 Q27315980-0EC2EF1E-2C25-47AD-B8EA-21883BB16D22 Q27320285-6893F065-EF99-49B2-85C1-828A045A29C3 Q27322396-C3D56708-0E5B-47E6-B275-FE5F0AB62FF9 Q27438184-4CF03EA2-DD0D-417A-8711-438900C039A0 Q27852587-F30C0EF8-AC98-4F7C-A456-C868BEE00642 Q28075791-89425C96-BF53-4345-952D-02A0A6606492 Q28282860-9A9D1EB9-2CA6-473D-BFF8-3079986E2969 Q28388257-7797EF4A-2549-413F-8915-D5DFCB373E17 Q28480588-69C630B0-D092-46AC-8C21-62EAFDD5D055

P2860

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

http://www.wikidata.org/entity/Q42457867

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@en

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@nl

type

label

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@en

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@nl

prefLabel

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@en

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@nl

P1433

Q42457867-6972E88F-21C1-4542-AA6E-D8F71A26D776

P1476

Q42457867-690FB03D-5911-4566-8695-ED8EF8CDAAF0

P2093

Q42457867-075828EF-A49D-4EAA-9334-8718BF8F9574

Q42457867-0A28A982-462C-4C54-92C2-D4EEEFFB9BF9

Q42457867-12FBD43C-1393-40E0-B169-E1B9FD845754

Q42457867-36129501-41C6-4844-98B5-299DEF06C930

Q42457867-447026DF-AEBB-41A8-A9FD-4DD1EC242CD5

Q42457867-679AC889-0B50-4702-AC48-813D691A35B2

Q42457867-843FE685-CEB3-4297-A2E8-F5D6ED86B78F

Q42457867-9894F81A-1B42-4B8C-B8E6-B7B8D478C0AA

Q42457867-A5CFFF96-0B70-4942-A628-BFECC3234414

Q42457867-A75A442A-0E1D-4EF8-BF01-DED802AA0EA0

P2860

Q42457867-3B1A21BC-6732-43B8-8B13-279C4036DF95

Q42457867-BA066B75-ECB8-4315-8766-4B883E3399E4

Q42457867-F0563129-D7E2-4B94-8B5B-7D1B2EA6FDD4

P2888

Q42457867-D3C32ECE-80BB-42DA-B82F-1693B64AC451

P304

Q42457867-0FA4C9AE-538A-47FE-B357-1B7AAD18CC3F

P31

Q42457867-9256C0B4-9065-461F-9FDB-F1ACD51A4A0A

P356

Q42457867-15519C5F-D26D-42EF-9952-0BCFC71B834F

P407

Q42457867-4F6FB9F0-7DAC-4430-AA6A-010E5CCF07C9

P433

Q42457867-BFFACF01-1077-4A12-87F3-C4C290034278

P478

Q42457867-FC8954AF-E24D-4559-8540-6FF7FC055263

P50

Q42457867-0130B65C-2DF7-4D16-980C-E74ADD7905DE

Q42457867-30BC12D1-8C23-4F2B-BE23-71B6B508FF30

Q42457867-68193628-B819-40F2-9050-BCE385316621

Q42457867-835F7A9F-47F1-4E66-9EFF-22C07A50E803

Q42457867-950FD43A-AF5E-4973-B20B-D6B92DF13A69

Q42457867-B058577F-36B0-4F3B-BE8C-A7CB65281E8F

Q42457867-C155DD64-B8E6-4DF2-8000-A3E23A1C76CE

P577

Q42457867-10EF12CA-CFE7-4F48-B5F6-1C3003900DEC

P5875

Q42457867-42EBF57E-B00B-467E-B72A-69CF58A105E5

P698

Q42457867-7C4BD8E6-0861-43BA-9DA7-21F72159D516

P356

P1433

Nature Medicine

P1476

Aberrant luminal progenitors a ...... nt in BRCA1 mutation carriers.

@en

P2093

Adam H Hart

http://www.w3.org/2001/XMLSchema#string

Audrey Partanen

http://www.w3.org/2001/XMLSchema#string

David E Gyorki

http://www.w3.org/2001/XMLSchema#string

Di Wu

http://www.w3.org/2001/XMLSchema#string

Frank Feleppa

http://www.w3.org/2001/XMLSchema#string

François Vaillant

http://www.w3.org/2001/XMLSchema#string

Jane E Visvader

http://www.w3.org/2001/XMLSchema#string

Juliet D French

http://www.w3.org/2001/XMLSchema#string

Lily I Huschtscha

http://www.w3.org/2001/XMLSchema#string

Marie-Liesse Asselin-Labat

http://www.w3.org/2001/XMLSchema#string

P2860

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.

Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells.

P2888

P304

907-913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2000

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Melissa A Brown

Geoffrey J. Lindeman

P577

2009-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26711301

http://www.w3.org/2001/XMLSchema#string

P698

19648928

http://www.w3.org/2001/XMLSchema#string